IL-1β inhibition in cardiovascular complications associated to diabetes mellitus

Biblos-e Archivo/Manakin Repository

Show simple item record Peiró, Concepción Lorenzo, Óscar Carraro, Raffaele Sánchez-Ferrer, Carlos F.
dc.contributor.other UAM. Departamento de Farmacología es_ES
dc.contributor.other UAM. Departamento de Medicina es_ES
dc.contributor.other Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) es_ES
dc.contributor.other Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) es_ES
dc.contributor.other Instituto de Investigación del Hospital de La Princesa (IP) es_ES 2017-11-16T12:32:52Z 2017-11-16T12:32:52Z 2017-06-13
dc.identifier.citation Frontiers in Pharmacology 8.June (2017): Article 363 en_US
dc.identifier.issn 1663-9812 es_ES
dc.description.abstract Diabetes mellitus (DM) is a chronic disease that affects nowadays millions of people worldwide. In adults, type 2 diabetes mellitus (T2DM) accounts for the majority of all diagnosed cases of diabetes. The course of the T2DM is characterized by insulin resistance and a progressive loss of β-cell mass. DM is associated with a number of related complications, among which cardiovascular complications and atherosclerosis are the main cause of morbidity and mortality in patients suffering from the disease. DM is acknowledged as a low-grade chronic inflammatory state characterized by the over-secretion of pro-inflammatory cytokines, including interleukin (IL)-1β, which reinforce inflammatory signals thus contributing to the development of complications. In this context, the pharmacological approaches to treat diabetes should not only correct hyperglycaemia, but also attenuate inflammation and prevent the development of metabolic and cardiovascular complications. Over the last years, novel biological drugs have been developed to antagonize the pathophysiological actions of IL-1β. The drugs currently used in clinical practice are anakinra, a recombinant form of the naturally occurring IL-1 receptor antagonist, the soluble decoy receptor rilonacept and the monoclonal antibodies canakinumab and gevokizumab. This review will summarize the main experimental and clinical findings obtained with pharmacological IL-1β inhibitors in the context of the cardiovascular complications of DM, and discuss the perspectives of IL-1β inhibitors as novel therapeutic tools for treating these patients. en_US
dc.description.sponsorship This work was supported by grants from Ministerio de Economía y Competitividad (SAF2014-52762-R) and Banco de Santander-Universidad Autónoma de Madrid (CEAL-AL/2015-17) en_US
dc.format.extent 13 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en
dc.publisher Frontiers Media en_US
dc.relation.ispartof Frontiers in Pharmacology en_US
dc.rights © 2017 Peiró, Lorenzo, Carraro and Sánchez-Ferrer es_ES
dc.subject.other Cardiovascular complications es_ES
dc.subject.other Diabetes en_US
dc.subject.other Inflammation en_US
dc.subject.other Interleukin-1 inhibitors en_US
dc.subject.other Interleukin-1ß en_US
dc.title IL-1β inhibition in cardiovascular complications associated to diabetes mellitus en_US
dc.type article en
dc.subject.eciencia Farmacia es_ES
dc.subject.eciencia Medicina es_ES
dc.relation.publisherversion es_ES
dc.identifier.doi 10.3389/fphar.2017.00363 es_ES
dc.identifier.publicationfirstpage 363-1 es_ES
dc.identifier.publicationissue June es_ES
dc.identifier.publicationlastpage 363-13 es_ES
dc.identifier.publicationvolume 8 es_ES
dc.relation.projectID Gobierno de España. SAF2014-52762-R es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en Reconocimiento es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Peiró Vallejo, M. Concepción (259003)

Files in this item


This item appears in the following Collection(s)

Show simple item record